MA46353A - Méthodes de traitement de l'infertilité féminine - Google Patents

Méthodes de traitement de l'infertilité féminine

Info

Publication number
MA46353A
MA46353A MA046353A MA46353A MA46353A MA 46353 A MA46353 A MA 46353A MA 046353 A MA046353 A MA 046353A MA 46353 A MA46353 A MA 46353A MA 46353 A MA46353 A MA 46353A
Authority
MA
Morocco
Prior art keywords
women
treatment methods
infertility treatment
infertility
methods
Prior art date
Application number
MA046353A
Other languages
English (en)
Inventor
Brendan Mark Johnson
Vijaykumar Reddy Rajasekhar
Laura Ann Williams
Original Assignee
Myovant Sciences Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myovant Sciences Gmbh filed Critical Myovant Sciences Gmbh
Publication of MA46353A publication Critical patent/MA46353A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
MA046353A 2016-09-30 2017-09-29 Méthodes de traitement de l'infertilité féminine MA46353A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662402150P 2016-09-30 2016-09-30
US201662402018P 2016-09-30 2016-09-30

Publications (1)

Publication Number Publication Date
MA46353A true MA46353A (fr) 2019-08-07

Family

ID=60143672

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046353A MA46353A (fr) 2016-09-30 2017-09-29 Méthodes de traitement de l'infertilité féminine

Country Status (9)

Country Link
US (3) US11013780B2 (fr)
EP (1) EP3518952A1 (fr)
JP (3) JP6982621B2 (fr)
AU (2) AU2017336338B2 (fr)
CA (1) CA3038865A1 (fr)
IL (2) IL311335A (fr)
MA (1) MA46353A (fr)
TW (2) TWI778979B (fr)
WO (1) WO2018060438A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4223298A3 (fr) 2013-03-15 2023-08-16 AbbVie Inc. Compositions pour le traitement des saignements menstruels lourds
CA3038865A1 (fr) * 2016-09-30 2018-04-05 Myovant Sciences Gmbh Methodes de traitement de l'infertilite feminine
US11690854B2 (en) 2018-04-19 2023-07-04 Abbvie Inc. Methods of treating heavy menstrual bleeding
US10695589B1 (en) * 2019-05-01 2020-06-30 Zaher Merhi Method and kit for home controlled ovarian stimulation for in vitro fertilization
CN113384581B (zh) * 2020-03-12 2023-11-14 成都倍特药业股份有限公司 一种包含促性腺激素释放激素拮抗剂的药物组合物
CN111772682B (zh) * 2020-07-10 2021-08-13 北京大学第三医院（北京大学第三临床医学院） 预测受试者出现卵巢储备新变化年限的系统和方法
CN221977148U (zh) 2023-02-28 2024-11-08 株式会社藤仓 包层除去装置
KR102821987B1 (ko) * 2024-10-24 2025-06-26 에이디텍 주식회사 베타 코어 단편 hCG를 유효성분으로 포함하는 난임 치료용 조성물

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173592B1 (en) * 1999-03-31 2012-05-08 Zentaris Ivf Gmbh Method for a programmed controlled ovarian stimulation protocol
JP4639052B2 (ja) * 2003-03-12 2011-02-23 武田薬品工業株式会社 性腺機能改善剤
US7754220B2 (en) * 2003-03-12 2010-07-13 Takeda Pharmaceutical Company Limited Methods of inhibiting secretion of follicle-stimulating hormone and testosterone
EP1646389B1 (fr) 2003-07-07 2008-09-10 Neurocrine Biosciences, Inc. Derives de pyrimidine-2, 4-dione utilises comme antagonistes du recepteur d'hormone liberant de la gonadotrophine
WO2005117939A2 (fr) * 2004-04-23 2005-12-15 Applied Research Systems Ars Holding N.V. Utilisation de ligands gpcr54 pour le traitement de l'infertilite
WO2006001499A2 (fr) 2004-06-25 2006-01-05 Takeda Pharmaceutical Company Limited Derives de metastine et leur utilisation
WO2007084211A2 (fr) * 2005-11-11 2007-07-26 The General Hospital Corporation Utilisation de ligands du gpr54 pour le traitement de troubles de la reproduction, de troubles proliferatifs et pour la contraception
AR058584A1 (es) 2005-12-22 2008-02-13 Takeda Pharmaceutical Derivados de metastina y uso de los mismos
US8404643B2 (en) * 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
MX2009010828A (es) 2007-04-06 2009-10-29 Neurocrine Biosciences Inc Antagonistas del receptor de la hormona liberadora de gonadotropina y metodos relacionados con los mismos.
US8765948B2 (en) 2007-11-07 2014-07-01 Neurocrine Biosciences, Inc. Processes for the preparation of uracil derivatives
US20110118172A1 (en) * 2008-04-24 2011-05-19 Takeda Pharmaceutical Company Limited Metastin derivative and use thereof
EP2275433B1 (fr) * 2008-04-30 2017-06-07 Kyoto University Dérivé de metastine et son utilisation
WO2010013762A1 (fr) 2008-07-30 2010-02-04 武田薬品工業株式会社 Dérivé de métastine et son utilisation
GEP20146001B (en) 2008-12-29 2014-01-10 Takeda Pharmaceuticals Co Cancer prophylactic/therapeutic agent
MX2012006441A (es) 2009-12-22 2012-06-28 Takeda Pharmaceutical Formulacion de liberacion sostenida.
EP2585091B1 (fr) 2010-06-25 2014-09-10 Takeda Pharmaceutical Company Limited Formule à libération prolongée comprenant un dérivé de metastin
EP2755690B1 (fr) * 2011-08-04 2020-04-01 Merck Sharp & Dohme B.V. Conjugués du kisspeptide avec un pentasaccharide
JO3092B1 (ar) * 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
CA3038865A1 (fr) 2016-09-30 2018-04-05 Myovant Sciences Gmbh Methodes de traitement de l'infertilite feminine

Also Published As

Publication number Publication date
EP3518952A1 (fr) 2019-08-07
JP2022020827A (ja) 2022-02-01
IL311335A (en) 2024-05-01
US11638740B2 (en) 2023-05-02
JP6982621B2 (ja) 2021-12-17
US11013780B2 (en) 2021-05-25
TW202300169A (zh) 2023-01-01
US20220088114A1 (en) 2022-03-24
AU2023200731A1 (en) 2023-03-09
IL265696B2 (en) 2024-08-01
IL265696B1 (en) 2024-04-01
JP2023029608A (ja) 2023-03-03
WO2018060438A1 (fr) 2018-04-05
US20200046797A1 (en) 2020-02-13
JP7583504B2 (ja) 2024-11-14
CA3038865A1 (fr) 2018-04-05
TWI855377B (zh) 2024-09-11
IL265696A (en) 2019-05-30
AU2017336338B2 (en) 2022-11-10
TWI778979B (zh) 2022-10-01
JP2019529573A (ja) 2019-10-17
TW201815409A (zh) 2018-05-01
AU2017336338A1 (en) 2019-05-16
US20230045718A1 (en) 2023-02-09
JP7212129B2 (ja) 2023-01-24

Similar Documents

Publication Publication Date Title
IL285722A (en) Methods for treating alzheimer's disease
EP3813808A4 (fr) Méthodes de traitement de la toxicomanie
MA45192A (fr) Traitement d'association
EP3645121A4 (fr) Méthodes de traitement de la maladie de huntington
EP3390634A4 (fr) Compositions et méthodes pour le traitement de maladies oculaires
EP3448504A4 (fr) Traitement de stimulation cérébrale pour dépression
EP3370721A4 (fr) Traitement de l'ostéoarthrite
EP3658139A4 (fr) Méthodes de traitement de maladies hépatiques
MA48996A (fr) Méthodes de traitement de maladies neurodégénératives
EP3285776A4 (fr) Méthodes de traitement d'infections bactériennes
EP3606531A4 (fr) Méthodes de traitement du cancer
MA53329A (fr) Méthodes de traitement de l'épilepsie
IL263433A (en) Methods for treating alzheimer's disease
EP3610026A4 (fr) Méthodes de traitement du cancer de la vessie
EP3713583A4 (fr) Méthodes et compositions pour le traitement de la peau
EP3443094A4 (fr) Procédés de réduction de l'expression de c9orf72
EP3519058C0 (fr) Compositions et méthodes de traitement des cheveux
EP3630101A4 (fr) Méthodes de traitement de maladies
EP3454793A4 (fr) Bobines de traitement d'anévrisme
FR3039368B1 (fr) Procede de traitement cosmetique
EP3634422A4 (fr) Méthodes de traitement de la leucodystrophie
HUE059387T2 (hu) Parkinson-kór kezelése
EP3007722A4 (fr) Méthodes de traitement de l'hypotension
EP3852816A4 (fr) Méthodes de traitement de cancer
EP3787625A4 (fr) Méthodes de traitement du cancer